Arnold & Porter (UK) Advises Norgine on Collaboration and Licensing Deal for Personalised Cell Therapy
LONDON, January 3, 2014 -- The London office of Arnold & Porter LLP recently advised European specialty pharmaceutical company Norgine B.V. ('Norgine') on a collaboration and exclusive licensing agreement with Austria-based biotech company Innovacell. The agreement covers Europe, the Middle East, North Africa and Southern Africa.
Life sciences commercial licensing partner Richard Dickinson led the work for Norgine. Norgine entered into an agreement for Innovacell's personalised cell-based therapy ICEF15. Through the collaboration Norgine will co-develop ICEF15 with Innovacell, and Norgine will commercialise the product. The clinical trial phase IIb is imminent, and the financial terms of the agreement have not been disclosed.